Candriam SCA’s Cymabay Therapeutics CBAY Stock Holding History

Candriam SCA’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-338,000	Closed	-$1.73M	–	810
2019 Q3	$1.73M	Sell	338,000 -40,000	-11%	-$242K	0.02%	522
2019 Q2	$2.69M	Sell	378,000 -600,000	-61%	-$6.79M	0.03%	449
2019 Q1	$13M	Hold	978,000	–	–	0.17%	142
2018 Q4	$7.7M	Buy	978,000 +20,000	+2%	+$190K	0.12%	200
2018 Q3	$10.6M	Buy	958,000 +488,000	+104%	+$6.06M	0.14%	180
2018 Q2	$6.31M	Buy	470,000 +225,000	+92%	+$2.82M	0.1%	255
2018 Q1	$3.18M	Buy	245,000 +110,000	+81%	+$1.37M	0.05%	374
2017 Q4	$1.24M	Buy	+135,000	New	+$1.15M	0.02%	552

Other funds holding CBAY

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return